Greet the day, folks, for another bustling and notably warm one lies ahead. One can gauge this by how our official mascots have modified their usual frolics across the sandy sprawling grounds of Pharmalot to prioritize huddling near indoor cooling devices. As for ourselves, we’re putting to test the bizarre concept of how a warm beverage might exert a cooling effect. Hence, we are revving up our reliable coffee pot — a fresh one arrived not too long ago — and preparing to indulge in a handful of refreshing drinks. For today, we’ve opted for the tantalizing pistachio creme. Don’t hesitate to engage in this ritual along with us.
The hour signals the kickoff of our routines. So, allow us to share a new selection of noteworthy topics for your consideration. We wish you enjoy an exhilarating day ahead and, by all means, keep the communication flowing. We extend to you the best of fortunes. Distinguished Jacqueline Corrigan-Curay, the prominent drug overseer at the U.S. Food and Drug Administration, is poised to retire from her role at the agency in July.
In her parting note, she detailed how the decision to exit the agency was inspired following a recent vacation and employed great strength to appreciate staff for their ‘consistent support, specifically during the trying periods of late.’ Corrigan-Curay’s term at the agency will extend for a few more weeks, devoid of any clarity concerning her successor.
Corrigan-Curay’s journey with the FDA initiated in 2016 when she began serving as the director of the office of medical policy at CDER. Following this position, she assumed the responsibilities of the CDER deputy director in 2021. It is noteworthy that the FDA has been witnessing a rapid outflow of top-level officials over time.
Several chose to take advantage of early retirement, while others found themselves pushed out by political nominees. This trend has led to a deficit in the number of FDA center directors, who usually held their positions resiliently under new administrations, leaving only a few behind at present.
A leading health authority from the U.S. Senate brings attention to a pressing concern. They suggest deferring this week’s assembly of a panel of vaccine advisors, outlining their inexperience and potential prejudice against certain vaccines as the reasons behind this recommendation.